Enpatoran Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 26, 2026

The clinical evidence base for Enpatoran comprises 2 peer-reviewed publications across 2 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Lupus Erythematosus, Cutaneous. Most recent publication: Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial., Lancet Rheumatol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial.
Morand EF, Werth VP, Wenzel J, et al. · Lancet Rheumatol · 2026
PubMed: PMID 42107375 · NCT05162586 · Lupus Erythematosus, Cutaneous
Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.
Morand EF, Dall'Era M, Sanchez-Guerrero J, et al. · Lancet · 2026
PubMed: PMID 42107374 · NCT05162586 · Lupus Erythematosus, Cutaneous

Publications by year

2026–2026: 2 publications.

2026

Publications by indication

Lupus Erythematosus, Cutaneous (2)

Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial.
Lancet Rheumatol · 2026 · PMID 42107375 · NCT05162586
Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.
Lancet · 2026 · PMID 42107374 · NCT05162586

Publications by journal

Lancet Rheumatol1 paper
Lancet1 paper

All Enpatoran publications (2)

2026 (2 papers)

Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial.
Morand EF, Werth VP, Wenzel J, et al. · Lancet Rheumatol · 2026 · Derived
PubMed: PMID 42107375 · NCT05162586 · Lupus Erythematosus, Cutaneous
Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.
Morand EF, Dall'Era M, Sanchez-Guerrero J, et al. · Lancet · 2026 · Derived
PubMed: PMID 42107374 · NCT05162586 · Lupus Erythematosus, Cutaneous

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Tue, 26 May 2026 18:10:37 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).